C-Myc immunohistochemistry in diffuse large B cell lymphoma

Research output: Contribution to journalArticle

Abstract

Diffuse large B cell lymphoma is a collection of different biologic entities with a common appearance but different clinical behaviors. The MYC oncogene is mutated in a subset of diffuse large B cell lymphoma and is also mutated in related entities such as Burkitt lymphoma. Recently, an antibody to the c-Myc oncoprotein has become available for immunohistochemistry, raising the possibility of a rapid, reproducible and inexpensive measure of MYC abnormality. Initial retrospective studies of these lymphomas suggest that the c-Myc status is clinically important for diagnosis and prognosis, particularly when used in conjunction with BCL2 immunohistochemistry. It is possible that therapy will be modified based in part on c-Myc status, once the appropriate prospective studies have been performed.

Original languageEnglish (US)
Pages (from-to)234-238
Number of pages5
JournalPathology Case Reviews
Volume19
Issue number5
DOIs
StatePublished - Dec 10 2014

Fingerprint

Lymphoma, Large B-Cell, Diffuse
Immunohistochemistry
Burkitt Lymphoma
Oncogene Proteins
Oncogenes
Lymphoma
Retrospective Studies
Prospective Studies
Antibodies
Therapeutics

Keywords

  • BCL2
  • Diffuse large B cell lymphoma
  • DLBCL
  • Immunohistochemistry
  • MYC

ASJC Scopus subject areas

  • Pathology and Forensic Medicine

Cite this

C-Myc immunohistochemistry in diffuse large B cell lymphoma. / Gocke, Christopher.

In: Pathology Case Reviews, Vol. 19, No. 5, 10.12.2014, p. 234-238.

Research output: Contribution to journalArticle

@article{13d2bbfc27274f0ea268b4bcd173c21c,
title = "C-Myc immunohistochemistry in diffuse large B cell lymphoma",
abstract = "Diffuse large B cell lymphoma is a collection of different biologic entities with a common appearance but different clinical behaviors. The MYC oncogene is mutated in a subset of diffuse large B cell lymphoma and is also mutated in related entities such as Burkitt lymphoma. Recently, an antibody to the c-Myc oncoprotein has become available for immunohistochemistry, raising the possibility of a rapid, reproducible and inexpensive measure of MYC abnormality. Initial retrospective studies of these lymphomas suggest that the c-Myc status is clinically important for diagnosis and prognosis, particularly when used in conjunction with BCL2 immunohistochemistry. It is possible that therapy will be modified based in part on c-Myc status, once the appropriate prospective studies have been performed.",
keywords = "BCL2, Diffuse large B cell lymphoma, DLBCL, Immunohistochemistry, MYC",
author = "Christopher Gocke",
year = "2014",
month = "12",
day = "10",
doi = "10.1097/PCR.0000000000000058",
language = "English (US)",
volume = "19",
pages = "234--238",
journal = "Pathology Case Reviews",
issn = "1082-9784",
publisher = "Lippincott Williams and Wilkins",
number = "5",

}

TY - JOUR

T1 - C-Myc immunohistochemistry in diffuse large B cell lymphoma

AU - Gocke, Christopher

PY - 2014/12/10

Y1 - 2014/12/10

N2 - Diffuse large B cell lymphoma is a collection of different biologic entities with a common appearance but different clinical behaviors. The MYC oncogene is mutated in a subset of diffuse large B cell lymphoma and is also mutated in related entities such as Burkitt lymphoma. Recently, an antibody to the c-Myc oncoprotein has become available for immunohistochemistry, raising the possibility of a rapid, reproducible and inexpensive measure of MYC abnormality. Initial retrospective studies of these lymphomas suggest that the c-Myc status is clinically important for diagnosis and prognosis, particularly when used in conjunction with BCL2 immunohistochemistry. It is possible that therapy will be modified based in part on c-Myc status, once the appropriate prospective studies have been performed.

AB - Diffuse large B cell lymphoma is a collection of different biologic entities with a common appearance but different clinical behaviors. The MYC oncogene is mutated in a subset of diffuse large B cell lymphoma and is also mutated in related entities such as Burkitt lymphoma. Recently, an antibody to the c-Myc oncoprotein has become available for immunohistochemistry, raising the possibility of a rapid, reproducible and inexpensive measure of MYC abnormality. Initial retrospective studies of these lymphomas suggest that the c-Myc status is clinically important for diagnosis and prognosis, particularly when used in conjunction with BCL2 immunohistochemistry. It is possible that therapy will be modified based in part on c-Myc status, once the appropriate prospective studies have been performed.

KW - BCL2

KW - Diffuse large B cell lymphoma

KW - DLBCL

KW - Immunohistochemistry

KW - MYC

UR - http://www.scopus.com/inward/record.url?scp=84916593396&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84916593396&partnerID=8YFLogxK

U2 - 10.1097/PCR.0000000000000058

DO - 10.1097/PCR.0000000000000058

M3 - Article

AN - SCOPUS:84916593396

VL - 19

SP - 234

EP - 238

JO - Pathology Case Reviews

JF - Pathology Case Reviews

SN - 1082-9784

IS - 5

ER -